Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach

BACKGROUND: Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor which raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol level, has been documented to increase mortality and cardiac events associated with adverse effects. However, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Shengjun, Geng, Qiang, Pan, Zhenyu, Li, Xin, Tie, Lu, Pan, Yan, Li, Xuejun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547811/
https://www.ncbi.nlm.nih.gov/pubmed/23228038
http://dx.doi.org/10.1186/1752-0509-6-152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547811/
https://www.ncbi.nlm.nih.gov/pubmed/23228038
http://dx.doi.org/10.1186/1752-0509-6-152

Ejemplares similares